Evidence map›Paper›PMID 34413955›Full record

ArticleACS medicinal chemistry letters2021

Discovery of Irbesartan Derivatives as BLT2 Agonists by Virtual Screening.

Victor Hernandez-Olmos, Jan Heering, Iris Bischoff-Kont, Alexander Kaps, Rinusha Rajkumar, Ting Liu, Robert Fürst, Dieter Steinhilber, Ewgenij Proschak

Open access · greenAbstract read
In one paragraph

Article in ACS medicinal chemistry letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. General Installation of (4Journal of the American Chemical Society · 2024
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Victor Hernandez-OlmosFraunhofer Institute for Translational Medicine and Phamacology ITMP, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany.
Jan HeeringFraunhofer Institute for Translational Medicine and Phamacology ITMP, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany.ORCID https://orcid.org/0000-0002-4922-1993
Iris Bischoff-KontInstitute of Pharmaceutical Biology, Goethe University Frankfurt, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany.
Alexander KapsFraunhofer Institute for Translational Medicine and Phamacology ITMP, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany.
Rinusha RajkumarFraunhofer Institute for Translational Medicine and Phamacology ITMP, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany.
Ting LiuFraunhofer Institute for Translational Medicine and Phamacology ITMP, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany.
Robert FürstInstitute of Pharmaceutical Biology, Goethe University Frankfurt, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany.
Dieter SteinhilberFraunhofer Institute for Translational Medicine and Phamacology ITMP, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany.
Ewgenij ProschakFraunhofer Institute for Translational Medicine and Phamacology ITMP, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany.ORCID https://orcid.org/0000-0003-1961-1859
Goethe University Frankfurt · DEFraunhofer Institute for Translational Medicine and Pharmacology · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leuktriene B4 receptor 2 (BLT2) is a G-protein coupled receptor modulation of which is discussed to be a therapeutic option for healing of intestinal lesions. In this work, new BLT2 agonists were identified by a virtual screening of a repurposing library and

Identifiers

PMID34413955
PMCPMC8366018
OpenAlexW3179377590

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.